Evidence map›Paper›PMID 35861670›Full record

ArticleInvestigative ophthalmology & visual science2022

Deletion of Protein Phosphatase 2A Accelerates Retinal Degeneration in GRK1- and Arr1-Deficient Mice.

Alexander V Kolesnikov, Jennings Luu, Hui Jin, Krzysztof Palczewski, Vladimir J Kefalov

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Stress resilience-enhancing drugs preserve tissue structure and function in degenerating retina via phosphodiesterase inhibition.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alexander V KolesnikovGavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, California, United States.
Jennings LuuGavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, California, United States.
Hui JinDepartment of Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States.
Krzysztof PalczewskiGavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, California, United States.
Vladimir J KefalovGavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, California, United States.
University of California, Irvine · USCase Western Reserve University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
STRUCTURAL STUDIES OF ARRESTINSR01EY009339 · NEI · UNIVERSITY OF WASHINGTON · PI KISER, PHILIP DAVID, PALCZEWSKI, KRZYSZTOF · 1992 to 2025
$16.0M
Use of systems pharmacology to prevent rod and cone photoreceptor degenerationR24EY027283 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI PALCZEWSKI, KRZYSZTOF · 2017 to 2021
$7.9M
Medical Scientist Training Program at Case Western Reserve UniversityT32GM152319 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI Heather Broihier, Alex Yee-Chen Huang · 2024 to 2026
$5.1M
Opsin signaling in mammalian rod photoreceptorsR01EY030912 · NEI · WASHINGTON UNIVERSITY · PI KEFALOV, VLADIMIR JIVKOV, PALCZEWSKI, KRZYSZTOF · 2020 to 2023
$1.6M
Identification of novel phosphodiesterase (PDE)-modulating compounds and characterization of associated cytoprotective pathways in lightdamagedretinaF30EY031566 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI LUU, JENNINGS C · 2021 to 2024
$209k
NEI NIH HHS F30 EY031566NEI NIH HHS R01 EY009339NEI NIH HHS R01 EY030912NEI NIH HHS R24 EY027283NIGMS NIH HHS T32 GM007250NIGMS NIH HHS T32 GM152319
6 · The paper itself

Abstract

Purpose: Light detection in retinal rod photoreceptors is initiated by activation of the visual pigment rhodopsin. A critical, yet often-overlooked, step enabling efficient perception of light is rhodopsin dephosphorylation mediated by protein phosphatase 2A (PP2A). PP2A deficiency has been reported to impair rhodopsin regeneration after phosphorylation by G protein receptor kinase 1 (GRK1) and binding of arrestin (Arr1), thereby delaying rod dark adaptation. However, its effects on the viability of photoreceptors in the absence of GRK1 and Arr1 remain unclear. Here, we investigated the effects of PP2A deficiency in the absence of GRK1 or Arr1, both of which have been implicated in Oguchi disease, a form of night blindness. Methods: Rod-specific mice lacking the predominant catalytic Cα-subunit of PP2A were crossed with the Grk1-/- or Arr1-/- strains to obtain double knockout lines. Rod photoreceptor viability was analyzed in histological cross-sections of the retina stained with hematoxylin and eosin, and rod function was evaluated by ex vivo electroretinography. Results: PP2A deficiency alone did not impair photoreceptor viability up to 12 months of age. Retinal degeneration was more pronounced in rods lacking GRK1 compared to rods lacking Arr1, and degeneration was accelerated in both Grk1-/- or Arr1-/- strains where PP2A was also deleted. In Arr1-/- mice, rod maximal photoresponse amplitudes were reduced by 80% at 3 months, and this diminution was enhanced further with concomitant PP2A deficiency. Conclusions: These results suggest that although PP2A is not required for the survival of rods, its deletion accelerates the degeneration induced by the absence of either GRK1 or Arr1.

Indexed as

ArrestinRetinal DegenerationAnimalsG-Protein-Coupled Receptor Kinase 1MiceMice, KnockoutProtein Phosphatase 2Retinal Rod Photoreceptor CellsRhodopsinArrestinG-Protein-Coupled Receptor Kinase 1Grk1 protein, mouseProtein Phosphatase 2Rhodopsin

Identifiers

PMID35861670
PMCPMC9315073
OpenAlexW4286498766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.